The Chain explores the lives, careers, research, and discoveries of protein engineers and scientists, the impact their work is having on the field, and where the industry is headed. Tune in to stay up-to-date on the newest advancements and to hear the stories that are impacting the world of biologics.
…
continue reading
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
…
continue reading
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
…
continue reading
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
…
continue reading
The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.
…
continue reading
Medical oncologist Dr Neil Love interviews oncology experts. Free NCPD credit hours are available.
…
continue reading
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoke ...
…
continue reading
Evaluating Biopharma taps into the insight and experience of biopharmaceutical leaders so today’s decision makers can leverage their knowledge, learn from their successes, and avoid repeating similar mistakes. This series offers a new guest and moderator with each episode and aims to equip executives and science leaders with the necessary information to make better business and process decisions. The Evaluating Biopharma podcast is a reproduction of content originally presented at recent Eva ...
…
continue reading
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, ...
…
continue reading

1
Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies
40:11
40:11
Play later
Play later
Lists
Like
Liked
40:11Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Da…
…
continue reading

1
Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2
58:21
58:21
Play later
Play later
Lists
Like
Liked
58:21Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.By Dr. Neil Love
…
continue reading

1
Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma
15:43
15:43
Play later
Play later
Lists
Like
Liked
15:43An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York. Sarah Maxwell, Audio Journal of Oncology: “An exciting, new immunotherapy treatment for multiple myeloma, was under discussion at the 2024 Ameri…
…
continue reading

1
Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
1:33:02
1:33:02
Play later
Play later
Lists
Like
Liked
1:33:02Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…
…
continue reading

1
Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
1:33:02
1:33:02
Play later
Play later
Lists
Like
Liked
1:33:02Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…
…
continue reading

1
Oncology Nursing Edition: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
1:33:03
1:33:03
Play later
Play later
Lists
Like
Liked
1:33:03Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (4:40) Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12…
…
continue reading

1
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
52:53
52:53
Play later
Play later
Lists
Like
Liked
52:53Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Result…
…
continue reading

1
How Pharmacists Can Enhance Comprehensive Patient-Centered Care for Patients With HR+/HER2- MBC and Comorbidities
16:41
16:41
Play later
Play later
Lists
Like
Liked
16:41In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including: Common comorbidities and complexities in managing patients with HR+/HER2- MBC Treatment landscape for patients with HR+/HER2- MBC Real-…
…
continue reading

1
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy (Companion Faculty ...
32:02
32:02
Play later
Play later
Lists
Like
Liked
32:02Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with m…
…
continue reading

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ...
19:06
19:06
Play later
Play later
Lists
Like
Liked
19:06In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…
…
continue reading

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer
18:34
18:34
Play later
Play later
Lists
Like
Liked
18:34In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…
…
continue reading

1
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
52:52
52:52
Play later
Play later
Lists
Like
Liked
52:52Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. CME information and select publications here.By Dr. Neil Love
…
continue reading

1
Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates
44:21
44:21
Play later
Play later
Lists
Like
Liked
44:21Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCR…
…
continue reading

1
Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates
44:21
44:21
Play later
Play later
Lists
Like
Liked
44:21Dr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. CME information and select publications here.By Dr. Neil Love
…
continue reading